All Outputs (7)

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis (2018)
Journal Article
Dand, N., Duckworth, M., Baudry, D., Russell, A., Curtis, C. J., Hyuck Lee, S., …Study Group, B. (2019). HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), 2120-2130. https://doi.org/10.1016/j.jaci.2018.11.038

BACKGROUND: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treat... Read More about HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland (2018)
Journal Article
Garcia-Doval, I., Descalzo, M., Mason, K., Cohen, A., Ormerod, A., Gómez-García, F., …Network, T. P. (2018). Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. British Journal of Dermatology, 179(4), 863-871. https://doi.org/10.1111/bjd.16715

Background Cancer risk following long‐term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. Objectives To assess a dose–response relationship between cumulative length of exposure to biological therapy and... Read More about Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Missing Information About Study Funding (2018)
Journal Article
Mason, K. J., Barker, J. N., Smith, C. H., Hampton, P. J., Lunt, M., McElhone, K., …Study Group, T. B. (2018). Missing Information About Study Funding. JAMA Dermatology, 154(7), 852. https://doi.org/10.1001/jamadermatol.2018.2319

In the Original Investigation titled “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible And Ineligible Patients in BADBIR,”1 published online March 28, 2018, there was information omitted regarding study fu... Read More about Missing Information About Study Funding.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (2018)
Journal Article
Mason. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581 - 588. https://doi.org/10.1001/jamadermatol.2018.0183

Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but... Read More about Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR..

509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Rutter, M., Warren, R., …Ashcroft, D. (2018). 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(5), S87. https://doi.org/10.1016/j.jid.2018.03.517

The association between biologics and major cardiovascular events (CVEs) in adult patients with plaque psoriasis is unclear. We used prospective cohort data from BADBIR to compared CVE risk associated with different therapies in participants recruite... Read More about 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain (2018)
Journal Article
Mason, K. J., O'Neill, T. W., Lunt, M., Jones, A. K. P., & McBeth, J. (2018). Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain. Scandinavian Journal of Pain, 18(1), 59-69. https://doi.org/10.1515/sjpain-2017-0109

Background and aims: Amplification of sensory signalling within the nervous system along with psychosocial factors contributes to the variation and severity of knee pain. Quantitative sensory testing (QST) is a non-invasive test battery that assesse... Read More about Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain.

Risk of cancer in patients with psoriasis on biological therapies: a systematic review (2018)
Journal Article
Peleva, E., Exton, L. S., Kelley, K., Kleyn, C. E., Mason, K. J., & Smith, C. H. (2018). Risk of cancer in patients with psoriasis on biological therapies: a systematic review. British Journal of Dermatology, 178(1), 103-113. https://doi.org/10.1111/bjd.15830

Background Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. Objectives To investigate the risk of cancer... Read More about Risk of cancer in patients with psoriasis on biological therapies: a systematic review.